Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Nivolumab in the treatment of Hodgkin lymphoma
Stephen M. Ansell
Hematology
Research output
:
Contribution to journal
›
Article
›
peer-review
38
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Nivolumab in the treatment of Hodgkin lymphoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Nivolumab
100%
Hodgkin Disease
75%
Reed-Sternberg Cells
41%
Brentuximab Vedotin
23%
Ligands
20%
Clinical Trials
19%
Epstein-Barr Virus Infections
17%
Therapeutic Uses
12%
Therapeutics
12%
Chromosomes
11%
Stem Cells
10%
Up-Regulation
10%
Transplants
9%
T-Lymphocytes
9%
Drug Therapy
8%
Population
5%
Neoplasms
4%